Do analysts recommend OSRH or SCNI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend SCNI or LABT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Lakewood-Amedex Biotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SCNI or LABT more profitable?

Company Net Margins Return on Equity Return on Assets Scinai Immunotherapeutics N/A N/A N/A Lakewood-Amedex Biotherapeutics N/A N/A N/A

Do analysts prefer SCNI or PMCB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Nuvilex 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SCNI or PMCB more profitable?

Nuvilex's return on equity of 0.25% beat Scinai Immunotherapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Scinai Immunotherapeutics N/A N/A N/A Nuvilex N/A 0.25% 0.18%

Do analysts rate SCNI or CDIO?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cardio Diagnostics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts recommend SCNI or SNGX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Scinai Immunotherapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Soligenix 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is SCNI or SNGX more profitable?

Scinai Immunotherapeutics' return on equity of 0.00% beat Soligenix's return on equity. Company Net Margins Return on Equity Return on Assets Scinai Immunotherapeutics N/A N/A N/A Soligenix N/A -180.25% -107.46%

Scinai Immunotherapeutics (SCNI) Competitors

$1.86 -0.09 (-4.62%)

As of 09/4/2026 04:00 PM Eastern

Compare

SCNI vs. OSRH, LABT, PMCB, CDIO, and SNGX

Should you buy Scinai Immunotherapeutics stock or one of its competitors? Scinai Immunotherapeutics's main competitors and comparable companies include OSR (OSRH), Lakewood-Amedex Biotherapeutics (LABT), Nuvilex (PMCB), Cardio Diagnostics (CDIO), and Soligenix (SNGX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Scinai Immunotherapeutics compare to OSR?

OSR (NASDAQ:OSRH) and Scinai Immunotherapeutics (NASDAQ:SCNI) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

55.3% of OSR shares are held by institutional investors. Comparatively, 58.4% of Scinai Immunotherapeutics shares are held by institutional investors. 36.9% of OSR shares are held by insiders. Comparatively, 60.9% of Scinai Immunotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Scinai Immunotherapeutics has a net margin of 0.00% compared to OSR's net margin of -593.15%. Scinai Immunotherapeutics' return on equity of 0.00% beat OSR's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
OSR	-593.15%	-8.36%	-6.24%
Scinai Immunotherapeutics	N/A	N/A	N/A

OSR has a beta of 0.5, meaning that its stock price is 50% less volatile than the broader market. Comparatively, Scinai Immunotherapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Scinai Immunotherapeutics has lower revenue, but higher earnings than OSR. OSR is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
OSR	$1.81M	4.37	-$27.06M	-$0.37	N/A
Scinai Immunotherapeutics	$1.49M	0.65	-$8.31M	-$95.34	N/A

In the previous week, OSR's average media sentiment score of 0.00 equaled Scinai Immunotherapeutics'average media sentiment score.

Company	Overall Sentiment
OSR	Neutral
Scinai Immunotherapeutics	Neutral

Summary

Scinai Immunotherapeutics beats OSR on 8 of the 11 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Lakewood-Amedex Biotherapeutics?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, earnings, risk, profitability, media sentiment, analyst recommendations, institutional ownership and valuation.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Lakewood-Amedex Biotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Lakewood-Amedex Biotherapeutics has lower revenue, but higher earnings than Scinai Immunotherapeutics. Lakewood-Amedex Biotherapeutics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.49M	0.65	-$8.31M	-$95.34	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	-$3.85M	-$4.75	N/A

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Lakewood-Amedex Biotherapeutics	N/A	N/A	N/A

58.4% of Scinai Immunotherapeutics shares are owned by institutional investors. 60.9% of Scinai Immunotherapeutics shares are owned by company insiders. Comparatively, 5.4% of Lakewood-Amedex Biotherapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Lakewood-Amedex Biotherapeutics had 4 more articles in the media than Scinai Immunotherapeutics. MarketBeat recorded 4 mentions for Lakewood-Amedex Biotherapeutics and 0 mentions for Scinai Immunotherapeutics. Lakewood-Amedex Biotherapeutics' average media sentiment score of 0.78 beat Scinai Immunotherapeutics' score of 0.00 indicating that Lakewood-Amedex Biotherapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Lakewood-Amedex Biotherapeutics	Positive

Summary

Scinai Immunotherapeutics and Lakewood-Amedex Biotherapeutics tied by winning 4 of the 8 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Nuvilex?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Nuvilex (NASDAQ:PMCB) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

Scinai Immunotherapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Nuvilex has a beta of 0.66, indicating that its share price is 34% less volatile than the broader market.

Nuvilex's return on equity of 0.25% beat Scinai Immunotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Nuvilex	N/A	0.25%	0.18%

In the previous week, Scinai Immunotherapeutics' average media sentiment score of 0.00 equaled Nuvilex'saverage media sentiment score.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Nuvilex	Neutral

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 34.2% of Nuvilex shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Comparatively, 11.0% of Nuvilex shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Scinai Immunotherapeutics has higher revenue and earnings than Nuvilex. Nuvilex is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.49M	0.65	-$8.31M	-$95.34	N/A
Nuvilex	N/A	N/A	-$19.42M	-$3.00	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Nuvilex	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Scinai Immunotherapeutics beats Nuvilex on 6 of the 9 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Cardio Diagnostics?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Cardio Diagnostics (NASDAQ:CDIO) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, analyst recommendations, profitability and dividends.

Cardio Diagnostics has lower revenue, but higher earnings than Scinai Immunotherapeutics. Cardio Diagnostics is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.49M	0.65	-$8.31M	-$95.34	N/A
Cardio Diagnostics	$10K	550.56	-$6.50M	-$2.92	N/A

Scinai Immunotherapeutics has a beta of 2.08, indicating that its share price is 108% more volatile than the broader market. Comparatively, Cardio Diagnostics has a beta of 2.28, indicating that its share price is 128% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cardio Diagnostics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 8.1% of Cardio Diagnostics shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by insiders. Comparatively, 9.0% of Cardio Diagnostics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Cardio Diagnostics' average media sentiment score of 1.89 beat Scinai Immunotherapeutics' score of 0.00 indicating that Cardio Diagnostics is being referred to more favorably in the news media.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Cardio Diagnostics	Very Positive

Scinai Immunotherapeutics has a net margin of 0.00% compared to Cardio Diagnostics' net margin of -43,133.33%. Scinai Immunotherapeutics' return on equity of 0.00% beat Cardio Diagnostics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Cardio Diagnostics	-43,133.33%	-82.28%	-76.03%

Summary

Scinai Immunotherapeutics beats Cardio Diagnostics on 7 of the 12 factors compared between the two stocks.

How does Scinai Immunotherapeutics compare to Soligenix?

Scinai Immunotherapeutics (NASDAQ:SCNI) and Soligenix (NASDAQ:SNGX) are both small-cap healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, valuation, earnings, profitability, media sentiment, analyst recommendations, risk and institutional ownership.

Scinai Immunotherapeutics has higher revenue and earnings than Soligenix. Soligenix is trading at a lower price-to-earnings ratio than Scinai Immunotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scinai Immunotherapeutics	$1.49M	0.65	-$8.31M	-$95.34	N/A
Soligenix	$120K	46.93	-$11.08M	-$0.98	N/A

In the previous week, Scinai Immunotherapeutics' average media sentiment score of 0.00 equaled Soligenix'saverage media sentiment score.

Company	Overall Sentiment
Scinai Immunotherapeutics	Neutral
Soligenix	Neutral

Scinai Immunotherapeutics has a beta of 2.08, meaning that its stock price is 108% more volatile than the broader market. Comparatively, Soligenix has a beta of 1.92, meaning that its stock price is 92% more volatile than the broader market.

Scinai Immunotherapeutics' return on equity of 0.00% beat Soligenix's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scinai Immunotherapeutics	N/A	N/A	N/A
Soligenix	N/A	-180.25%	-107.46%

58.4% of Scinai Immunotherapeutics shares are held by institutional investors. Comparatively, 3.6% of Soligenix shares are held by institutional investors. 60.9% of Scinai Immunotherapeutics shares are held by company insiders. Comparatively, 1.9% of Soligenix shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scinai Immunotherapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Soligenix	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Scinai Immunotherapeutics beats Soligenix on 8 of the 10 factors compared between the two stocks.

Get Scinai Immunotherapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SCNI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SCNI vs. The Competition

Export

Metric	Scinai Immunotherapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$1.01M	$4.03B	$7.28B	$12.92B
Dividend Yield	N/A	3.60%	2.54%	8.90%
P/E Ratio	-0.02	12.65	272.43	25.42
Price / Sales	0.65	1,327.03	616.81	89.65
Price / Cash	N/A	107.40	77.39	52.28
Price / Book	0.16	16.15	12.85	6.17
Net Income	-$8.31M	-$22.76M	$3.47B	$349.50M
7 Day Performance	-25.90%	0.30%	0.97%	-0.15%
1 Month Performance	-25.60%	8.24%	5.46%	1.02%
1 Year Performance	-87.60%	49.08%	24.28%	14.50%

Scinai Immunotherapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SCNI Scinai Immunotherapeutics	0.3291 of 5 stars	$1.86 -4.6%	N/A	-88.1%	$1.01M	$1.49M	N/A	20	Short Interest Increase
OSRH OSR	0.3305 of 5 stars	$0.17 +1.5%	N/A	-62.0%	$5.88M	$1.81M	N/A	N/A	Gap Down
LABT Lakewood-Amedex Biotherapeutics	0.7571 of 5 stars	$2.49 +1.6%	N/A	N/A	$5.81M	N/A	N/A	5	News Coverage Positive News Analyst Revision Gap Down
PMCB Nuvilex	0.8468 of 5 stars	$0.54 -0.1%	N/A	-47.9%	$5.80M	N/A	N/A	4	Positive News Analyst Downgrade
CDIO Cardio Diagnostics	0.9082 of 5 stars	$1.87 -3.1%	N/A	-49.6%	$5.71M	$14.45K	N/A	1	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SCNI) was last updated on 9/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scinai Immunotherapeutics (SCNI) Competitors

SCNI vs. OSRH, LABT, PMCB, CDIO, and SNGX

How does Scinai Immunotherapeutics compare to OSR?

Summary

How does Scinai Immunotherapeutics compare to Lakewood-Amedex Biotherapeutics?

Summary

How does Scinai Immunotherapeutics compare to Nuvilex?

Summary

How does Scinai Immunotherapeutics compare to Cardio Diagnostics?

Summary

How does Scinai Immunotherapeutics compare to Soligenix?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNI vs. The Competition

Scinai Immunotherapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scinai Immunotherapeutics (SCNI) Competitors

SCNI vs. OSRH, LABT, PMCB, CDIO, and SNGX

How does Scinai Immunotherapeutics compare to OSR?

Do insiders & institutionals hold more shares of OSRH or SCNI?

Is OSRH or SCNI more profitable?

Which has more risk & volatility, OSRH or SCNI?

Do analysts recommend OSRH or SCNI?

Which has better valuation & earnings, OSRH or SCNI?

Does the media refer more to OSRH or SCNI?

Summary

How does Scinai Immunotherapeutics compare to Lakewood-Amedex Biotherapeutics?

Do analysts recommend SCNI or LABT?

Which has better valuation & earnings, SCNI or LABT?

Is SCNI or LABT more profitable?

Do institutionals & insiders have more ownership in SCNI or LABT?

Does the media refer more to SCNI or LABT?

Summary

How does Scinai Immunotherapeutics compare to Nuvilex?

Which has more volatility and risk, SCNI or PMCB?

Is SCNI or PMCB more profitable?

Does the media refer more to SCNI or PMCB?

Do institutionals & insiders hold more shares of SCNI or PMCB?

Which has stronger valuation & earnings, SCNI or PMCB?

Do analysts prefer SCNI or PMCB?

Summary

How does Scinai Immunotherapeutics compare to Cardio Diagnostics?

Which has stronger valuation and earnings, SCNI or CDIO?

Which has more risk and volatility, SCNI or CDIO?

Do analysts rate SCNI or CDIO?

Do insiders and institutionals believe in SCNI or CDIO?

Does the media refer more to SCNI or CDIO?

Is SCNI or CDIO more profitable?

Summary

How does Scinai Immunotherapeutics compare to Soligenix?

Which has better earnings & valuation, SCNI or SNGX?

Does the media refer more to SCNI or SNGX?

Which has more volatility and risk, SCNI or SNGX?

Is SCNI or SNGX more profitable?

Do institutionals and insiders have more ownership in SCNI or SNGX?

Do analysts recommend SCNI or SNGX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SCNI vs. The Competition

Scinai Immunotherapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools